US Patent 10875913 Methods of treatment using activatable anti-EGFR antibodies
Patent 10875913 was granted and assigned to CytomX Therapeutics on December, 2020 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10875913 Methods of treatment using activatable anti-EGFR antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.